Total Payments
$184,022
2024 Payments
$2,664
Companies
78
Transactions
1,061
Medicare Patients
12,148
Medicare Billing
$7.0M
Payment Breakdown by Category
Other$101,217 (55.0%)
Consulting$50,233 (27.3%)
Food & Beverage$16,881 (9.2%)
Travel$15,373 (8.4%)
Education$318.56 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $97,945 | 47 | 53.2% |
| Consulting Fee | $50,233 | 27 | 27.3% |
| Food and Beverage | $16,881 | 905 | 9.2% |
| Travel and Lodging | $15,373 | 48 | 8.4% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $1,740 | 1 | 0.9% |
| Long term medical supply or device loan | $1,531 | 17 | 0.8% |
| Education | $318.56 | 16 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $88,016 | 198 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $57,557 | 131 | $0 (2024) |
| Gilead Sciences, Inc. | $13,619 | 23 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $8,488 | 48 | $0 (2024) |
| Immunomedics, Inc. | $2,500 | 2 | $0 (2020) |
| Celgene Corporation | $1,393 | 50 | $0 (2024) |
| Amgen Inc. | $1,146 | 43 | $0 (2023) |
| Rigel Pharmaceuticals, Inc. | $1,025 | 3 | $0 (2020) |
| Merck Sharp & Dohme LLC | $1,018 | 57 | $0 (2024) |
| Seattle Genetics, Inc. | $974.29 | 11 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,664 | 135 | PFIZER INC. ($229.40) |
| 2023 | $2,886 | 154 | Novartis Pharmaceuticals Corporation ($405.25) |
| 2022 | $8,656 | 92 | Novartis Pharmaceuticals Corporation ($2,881) |
| 2021 | $22,820 | 30 | Gilead Sciences, Inc. ($11,371) |
| 2020 | $13,712 | 56 | Novartis Pharmaceuticals Corporation ($6,024) |
| 2019 | $42,932 | 186 | Novartis Pharmaceuticals Corporation ($34,296) |
| 2018 | $56,451 | 226 | Novartis Pharmaceuticals Corporation ($27,082) |
| 2017 | $33,902 | 182 | Novartis Pharmaceuticals Corporation ($16,050) |
All Payment Transactions
1,061 individual payment records from CMS Open Payments — Page 1 of 43
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | Pharmacosmos Therapeutics Inc. | COSELA (Drug) | Food and Beverage | In-kind items and services | $19.07 | General |
| Category: HEMATOLOGY | ||||||
| 12/12/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $26.34 | General |
| Category: Oncology | ||||||
| 12/11/2024 | PFIZER INC. | XTANDI (Drug), TALZENNA, ORGOVYX | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $27.27 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/05/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $28.74 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $24.10 | General |
| 12/03/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $17.13 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Genentech USA, Inc. | Polivy (Biological) | Food and Beverage | In-kind items and services | $17.10 | General |
| Category: BioOncology | ||||||
| 11/27/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $11.48 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/26/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $29.51 | General |
| 11/25/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $24.93 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $20.37 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $20.10 | General |
| Category: Oncology | ||||||
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.37 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $35.63 | General |
| Category: Hematology | ||||||
| 11/11/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $27.39 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $21.51 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $21.33 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $17.75 | General |
| Category: Oncology | ||||||
| 11/04/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $22.30 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $22.98 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $32.50 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $26.34 | General |
| Category: Oncology | ||||||
| 10/28/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), REBLOZYL, WELIREG | Food and Beverage | In-kind items and services | $26.99 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.09 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 42 | 2,247 | 87,698 | $5.0M | $1.5M |
| 2022 | 58 | 2,866 | 78,477 | $5.2M | $1.6M |
| 2021 | 66 | 3,611 | 59,612 | $5.1M | $1.7M |
| 2020 | 67 | 3,424 | 70,580 | $6.5M | $2.1M |
Total Patients
12,148
Total Services
296,367
Medicare Billing
$7.0M
Procedure Codes
233
All Medicare Procedures & Services
233 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 21 | 27,400 | $3.8M | $1.2M | 31.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 24 | 3,900 | $198,900 | $72,206 | 36.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 80 | 524 | $198,072 | $50,175 | 25.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 177 | 434 | $147,126 | $41,193 | 28.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 286 | 614 | $146,746 | $39,300 | 26.8% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 15 | 20,250 | $60,750 | $17,399 | 28.6% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 25 | 10,400 | $52,000 | $14,244 | 27.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 74 | 84 | $46,704 | $11,389 | 24.4% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 291 | 1,322 | $38,338 | $10,060 | 26.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 292 | 1,102 | $9,918 | $9,257 | 93.3% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 11 | 57 | $32,034 | $7,638 | 23.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 43 | 43 | $25,155 | $7,172 | 28.5% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 29 | 137 | $24,386 | $6,640 | 27.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 43 | 102 | $20,094 | $6,323 | 31.5% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 93 | 547 | $33,367 | $6,320 | 18.9% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 15 | 14,790 | $59,160 | $5,805 | 9.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 58 | 116 | $21,924 | $5,415 | 24.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 105 | 359 | $24,771 | $3,735 | 15.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 39 | 114 | $9,576 | $2,476 | 25.9% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 33 | 75 | $11,700 | $2,064 | 17.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 17 | 17 | $7,701 | $1,947 | 25.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 20 | $5,700 | $1,884 | 33.0% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 12 | 41 | $6,970 | $1,725 | 24.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 12 | 12 | $5,688 | $1,677 | 29.5% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 19 | 70 | $5,530 | $1,509 | 27.3% |
About Dr. Eric Harris, D.O
Dr. Eric Harris, D.O is a Hematology healthcare provider based in Daytona Beach, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/30/2008. The National Provider Identifier (NPI) number assigned to this provider is 1902068158.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Harris, D.O has received a total of $184,022 in payments from pharmaceutical and medical device companies, with $2,664 received in 2024. These payments were reported across 1,061 transactions from 78 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($97,945).
As a Medicare-enrolled provider, Harris has provided services to 12,148 Medicare beneficiaries, totaling 296,367 services with total Medicare billing of $7.0M. Data is available for 4 years (2020–2023), covering 233 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology
- Location Daytona Beach, FL
- Active Since 06/30/2008
- Last Updated 02/03/2026
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1902068158
Products in Payments
- MEKINIST (Drug) $84,650
- OPDIVO (Biological) $38,173
- Trodelvy (Drug) $15,940
- IMFINZI (Drug) $7,851
- KISQALI (Drug) $1,819
- Tavalisse (Drug) $1,025
- ADCETRIS (Biological) $979.71
- KEYTRUDA (Biological) $880.88
- IMLYGIC (Biological) $649.87
- TAFINLAR (Drug) $383.16
- JAKAFI (Drug) $331.13
- PROMACTA (Drug) $297.09
- Lenvima (Drug) $270.98
- IMBRUVICA (Drug) $245.53
- REBLOZYL (Biological) $238.33
- IMFINZI (Biological) $229.50
- Pomalyst (Drug) $219.11
- Revlimid (Drug) $205.56
- XTANDI (Drug) $193.94
- ZEJULA (Drug) $191.07
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.